Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 6/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.75 |
| ▸ | GHSR | Q92847 | 14/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5793518 | 0.76 | CYP2D6 (0.71) | CYP2D6HTR2CGHSRKCNH2CYP3A4 | |
| SCHEMBL5794423 | 0.75 | CYP2D6 (0.79) | CYP2D6HTR2CGHSRKCNH2CYP3A4 | |
| SCHEMBL5792759 | 0.74 | CYP2D6 (0.65) | CYP2D6HTR2CGHSRKCNH2CYP3A4 | |
| SCHEMBL5792756 | 0.74 | CYP2D6 (0.65) | CYP2D6HTR2CGHSRKCNH2CYP3A4 | |
| SCHEMBL5805037 | 0.74 | CYP2D6 (0.65) | CYP2D6HTR2CGHSRKCNH2CYP3A4 | |
| SCHEMBL5792437 | 0.73 | CYP2D6 (0.64) | CYP2D6HTR2CGHSRKCNH2CYP3A4 | |
| SCHEMBL5794800 | 0.73 | CYP2D6 (0.60) | CYP2D6HTR2CGHSRKCNH2CYP3A4 | |
| SCHEMBL21632609 | 0.73 | GHSR (0.85) | CYP2D6HTR2CGHSRKCNH2CYP3A4 | |
| SCHEMBL21632610 | 0.73 | GHSR (0.85) | CYP2D6HTR2CGHSRKCNH2CYP3A4 | |
| SCHEMBL5794926 | 0.72 | CYP2D6 (0.69) | CYP2D6HTR2CGHSRKCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006012577-A2 | QUINAZOLINONE DERIVATIVES USEFUL FOR THE REGULATION OF GLUCOSE HOMEOSTASIS AND FOOD INTAKE | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |